Riverain’s ClearRead CT Software, the Most Clinically Validated in the Industry, Helps Maintain Efficiency, Accuracy and Consistency in Lung Cancer Screening
Riverain Technologies announced today it has further expanded its footprint with the VA through the award for Veterans Integrated Service Networks (VISN) 8 in Florida, southern Georgia, and Puerto Rico. VISN 8 is the twelfth VISN to use Riverain Technologies lung nodule detection software, ClearRead.
ClearRead CT is the only FDA cleared concurrent reading device incorporating vessel suppression. It is based on deep learning that aids in detecting and characterizing solid, part-solid, and ground glass lung nodules. ClearRead CT is proven to improve nodule search efficiency by 26% and increase reading accuracy by 29%. Early detection and diagnoses is critical in the management of lung disease.(1)
“Riverain Technologies is proud of our continuing expansion in Veteran Hospitals to aid in the care of our veterans. We are honored to assist in veteran’s health needs,” said Steve Worrell, CEO.
As stated in VA works to raise awareness for lung cancer screening in Veterans(2), approximately 900,000 Veterans are at risk of developing lung cancer. The risk is due to aging, a smoking history, and environmental exposures during or after military service. Each year, VA diagnoses 7,700 veterans with lung cancer.
Riverain Technologies is a leader in clinical AI commercialization, offering five clinically proven FDA cleared products that incorporate state-of-the-art machine learning technologies.
1: Lo, S. B., Freedman, M. T., Gillis, L. B., White, C. S., & Mun, S. K. (2018). JOURNAL CLUB: Computer-Aided Detection of Lung Nodules on CT With a Computerized Pulmonary Vessel Suppressed Function. American Journal of Roentgenology, 210(3), 480–488. doi: 10.2214/ajr.17.18718.